Prostate Cancer (PCa) is the second most common cancer among men and the fifth greatest cause of cancer related mortality globally. More than 80% of PCa cases are currently diagnosed as localised disease, but up to a third of these patients will later recur and develop. Because androgens and Androgen Receptor (AR) signalling are so critical in normal prostate development and PCa progression, Androgen Deprivation Therapy (ADT) is the most common treatment for advanced PCa. Despite an initial response to ADT, individuals frequently develop resistant and advance to an aggressive disease state known as Castration-Resistant Pca (CRPC) between 12 to 30 months. Despite the fact that treatment with next generation androgen signalling inhibitors has improved the outcome, these patients still lack curative medicines, necessitating the urgent development of novel therapeutic techniques.